NEW YORK (AP) ¿ Shares of Santarus Inc. soared in premarket activity Wednesday after the Food and Drug Administration approved an over-the-counter version of the company's prescription heartburn drug Zegerid. The stock gained $1.13, or 26.3 percent, to $5.42 ahead of Wednesday's market open. The stock has ranged from $1.05 to $4.39 over the past year. The company had partnered with Schering-Plough Corp. on the over-the-counter version of Zegerid. Merck & Co. took over the application after buying Schering-Plough in November. San Diego-based Santarus stands to receive a $20 million milestone payment and could also get up to $37.5 million in sales milestone payments, along with royalties on sales. Santarus recorded revenue of $130.2 million in 2008. Merck said Zegerid OTC will be available in the first half of 2010.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Food & Drink
Beyond Meat Slides After Andrew Left's Citron Slams Stock in Tweet
Newly public meat-alternative company sees shares lower on short-seller's critique.
PepsiCo Still Looks Bullish - A Higher Price Target Seen
How do the charts look with their latest advance?
Del Monte Foods Targets Amazon Generation With New Products
CEO Greg Longstreet sat down with TheStreet to discuss how his company is adapting to changing consumer habits.
Is Beyond Meat's Rapid Run a Sign of an IPO-Driven Bubble?
Whether you're vegan or not, Beyond Meat's valuation is certainly hard to swallow at this point and its making the 2019 IPO picture somewhat unpalatable overall.